Journal Publication

Serum CTRP7 tracks kidney damage severity, tied to dapagliflozin benefit in DKD

A 108-patient cross-sectional study links rising CTRP7 to worsening diabetic kidney disease, and a 48-patient follow-on ties 12 weeks of dapagliflozin to lower albuminuria and reduced oxidative stress markers.

By AppliedXLJuly 13, 2026

Executive Summary

A circulating protein rises in step with diabetic kidney disease severity, and combining it with routine clinical measures produced a predictive score with an AUC of 0.913 for identifying patients at risk.
Patients started on a widely used SGLT2 inhibitor showed lower albuminuria and blood pressure alongside markers consistent with reduced oxidative stress after twelve weeks.
The treatment observations came from a single uncontrolled group followed over a short window, so the biochemical changes cannot yet be attributed to the drug alone versus other concurrent care.
The results support using a blood-based marker alongside standard measures to flag kidney disease risk earlier, and are consistent with known renal benefits of this drug class in diabetic kidney disease.

The question

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a diabetes drug class taken by mouth, are known to slow kidney disease progression in patients with diabetic kidney disease (DKD), but the early clinical and biological changes that follow treatment initiation in routine practice are less studied. This study asked whether a circulating protein, serum CTRP7, tracks with DKD severity and whether starting dapagliflozin, an SGLT2 inhibitor, produces measurable early changes in kidney and oxidative-stress markers. Serum

How it was done

The study used a two-phase design. The cross-sectional phase enrolled 108 participants split into healthy controls, people with type 2 diabetes but no kidney disease, and people with diabetic kidney disease, comparing serum CTRP7 levels across the three groups. The longitudinal phase followed 48 patients with diabetic kidney disease for 12 weeks after starting dapagliflozin, tracking urinary albumin-to-creatinine ratio (a measure of kidney protein leakage), blood pressure, and oxidative-stress markers including malondialdehyde and superoxide dismutase. Serum

The results

Serum CTRP7 increased progressively from healthy controls to diabetics without kidney disease to diabetic kidney disease patients, tracking with disease severity. A nomogram combining CTRP7 with systolic blood pressure, glycated hemoglobin, and body mass index achieved an AUC of 0.913 for identifying diabetic kidney disease risk. After 12 weeks of dapagliflozin, the urinary albumin-to-creatinine ratio and blood pressure both fell, and the changes came alongside lower malondialdehyde and higher superoxide dismutase, markers consistent with reduced oxidative stress. Serum

Reading the biomarker signal

The oxidative-stress finding carries its own weight alongside the albuminuria result: two markers on opposite sides of the same oxidative-stress pathway, one falling and one rising, moved together with the kidney-function improvement in the same 48 patients over the same 12 weeks. That internal consistency is what a candidate biomarker needs to earn further study, even absent a comparator arm. Serum

What it extends

The albuminuria and blood-pressure reductions are consistent with the established renal-protective effect of SGLT2 inhibitors in diabetic kidney disease, extending that known benefit into an early, 12-week clinical-practice window rather than establishing a new mechanism. Serum

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.